2021
Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma
Lechner M, Takahashi Y, Turri-Zanoni M, Liu J, Counsell N, Hermsen M, Kaur RP, Zhao T, Ramanathan M, Schartinger VH, Emanuel O, Helman S, Varghese J, Dudas J, Riechelmann H, Sprung S, Haybaeck J, Howard D, Engel NW, Stewart S, Brooks L, Pickles JC, Jacques TS, Fenton TR, Williams L, Vaz FM, O'Flynn P, Stimpson P, Wang S, Hannan SA, Unadkat S, Hughes J, Dwivedi R, Forde CT, Randhawa P, Gane S, Joseph J, Andrews PJ, Royle G, Franchi A, Maragliano R, Battocchio S, Bewicke-Copley H, Pipinikas C, Webster A, Thirlwell C, Ho D, Teschendorff A, Zhu T, Steele CD, Pillay N, Vanhaesebroeck B, Mohyeldin A, Fernandez-Miranda J, Park KW, Le QT, West RB, Saade R, Manes RP, Omay SB, Vining EM, Judson BL, Yarbrough WG, Sansovini M, Silvia N, Grassi I, Bongiovanni A, Capper D, Schüller U, Thavaraj S, Sandison A, Surda P, Hopkins C, Ferrari M, Mattavelli D, Rampinelli V, Facchetti F, Nicolai P, Bossi P, Henriquez OA, Magliocca K, Solares CA, Wise SK, Llorente JL, Patel ZM, Nayak JV, Hwang PH, Lacy PD, Woods R, O'Neill JP, Jay A, Carnell D, Forster MD, Ishii M, London NR, Bell DM, Gallia GL, Castelnuovo P, Severi S, Lund VJ, Hanna EY. Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma. European Journal Of Cancer 2021, 162: 221-236. PMID: 34980502, PMCID: PMC9554673, DOI: 10.1016/j.ejca.2021.09.046.Peer-Reviewed Original ResearchConceptsPeptide radionuclide receptor therapyProphylactic neck irradiationDisease-free survivalOlfactory neuroblastomaSomatostatin receptor 2Stable diseaseAdjuvant radiotherapyNeck irradiationOverall survivalReceptor 2Potential efficacyPeptide receptor radionuclide therapyReceptor radionuclide therapyMultivariable survival analysisPertinent clinical dataClinical trial dataKey prognostic markersNodal recurrenceClinical outcomesClinicopathological characteristicsT stagePrognostic valueReceptor therapyDisease stageNeuroblastoma patients
2013
KRAS Mutations are Associated With Specific Morphologic Features in Colon Cancer
Gunal A, Hui P, Kilic S, Xu R, Jain D, Mitchell K, Robert M, Kenney B. KRAS Mutations are Associated With Specific Morphologic Features in Colon Cancer. Journal Of Clinical Gastroenterology 2013, 47: 509-514. PMID: 23090042, DOI: 10.1097/mcg.0b013e3182703030.Peer-Reviewed Original ResearchConceptsKRAS mutation statusKRAS mutationsSpecific morphologic featuresColon cancerMorphologic featuresMutation statusAnti-epidermal growth factor receptor therapyDNA mismatch repair gene mutationsPeritumoral lymphocytic responseT3-T4 statusStage IV diseaseMismatch repair gene mutationsColon cancer resectionTime of resectionRight-sided locationRepair gene mutationsPearson χ2 testAdenocarcinoma morphologyKRAS testingCancer resectionLymphovascular invasionHistologic featuresReceptor therapyLymphocytic responseHistologic characteristics
2010
Molecular Analysis of Non–Small Cell Lung Cancer Identifies Subsets with Different Sensitivity to Insulin-like Growth Factor I Receptor Inhibition
Gualberto A, Dolled-Filhart M, Gustavson M, Christiansen J, Wang YF, Hixon ML, Reynolds J, McDonald S, Ang A, Rimm DL, Langer CJ, Blakely J, Garland L, Paz-Ares LG, Karp DD, Lee AV. Molecular Analysis of Non–Small Cell Lung Cancer Identifies Subsets with Different Sensitivity to Insulin-like Growth Factor I Receptor Inhibition. Clinical Cancer Research 2010, 16: 4654-4665. PMID: 20670944, PMCID: PMC2952544, DOI: 10.1158/1078-0432.ccr-10-0089.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, MonoclonalAntineoplastic AgentsCarcinoma, Non-Small-Cell LungClinical Trials, Phase II as TopicDrug Resistance, NeoplasmFemaleHormone AntagonistsHumansImmunoglobulins, IntravenousInsulin-Like Growth Factor IMaleMiceMolecular Diagnostic TechniquesNIH 3T3 CellsPrognosisRetrospective StudiesTissue Array AnalysisConceptsNon-small cell lung cancerPhase II studySquamous cell tumorsIGF-IRII studyCell tumorsStage IIIB/IV non-small cell lung cancerAdvanced non-small cell lung cancerCell lung cancerIGF-IR pathwayIGF-IR inhibitionIGF-IR expressionCombination of chemotherapyHigh response rateEpidermal growth factor receptorEpithelial-like tumorsInsulin receptor substrate-1Growth factor receptorHistologic subtypeTransitional tumorsReceptor therapyIGF-IILung cancerReceptor inhibitionIGF-IIRMeasurement of conatumumab‐induced apoptotic activity in tumors by fine needle aspirate sampling
Zoog SJ, Y. C, Kaplan‐Lefko P, Hawkins JM, Moriguchi J, Zhou L, Pan Y, Hsu C, Friberg G, Herbst R, Hill J, Juan G. Measurement of conatumumab‐induced apoptotic activity in tumors by fine needle aspirate sampling. Cytometry Part A 2010, 77A: 849-860. PMID: 20623688, DOI: 10.1002/cyto.a.20940.Peer-Reviewed Original ResearchConceptsFine needle aspiratesDeath receptor 5Needle aspiratesNonsmall cell lung cancer patientsCell lung cancer patientsCaspase-3 activationLung cancer patientsTumor necrosis factorCaspase-3Tumor-bearing miceTumor cell deathReceptor therapyPharmacodynamic markersCancer patientsDrug exposureClinical trialsCaspase 3/7 activityNecrosis factorColo205 xenograftsClinical investigationReceptor 5FNA biopsyTumor typesPharmacological impactClinical setting
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply